First Berlin Equity Research publishes independent analysis of Cyxone
Cyxone (publ), a biotech company in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first quarter of 2022 and was published on 16 May 2022. The report in English can be read in its entirety on the Cyxone’s website . Contact Tara Heitner, CEOTel: +46 (0)70 781 88 08Email: tara.heitner@cyxone.com About Cyxone Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO)